FDA OKs Mylan's generic migraine tablets

01/3/2013 | Pharmaceutical Business Review Online

Mylan Pharmaceuticals has won FDA approval for its rizatriptan benzoate orally disintegrating tablets and rizatriptan benzoate tablets to address migraine with or without aura in adults. The drugs are generic formulations of Merck's Maxalt MLT and Maxalt.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care